<DOC>
	<DOCNO>NCT01689142</DOCNO>
	<brief_summary>Primary Objective : To compare efficacy new formulation insulin glargine Lantus term change HbA1c baseline endpoint ( schedule month 6 [ week 26 ] ) japanese patient type 2 diabetes mellitus . Secondary Objectives : To compare new formulation insulin glargine Lantus term change fast plasma glucose ( FPG ) , preinjection plasma glucose , 8-point self-measured plasma glucose ( SMPG ) profile . To compare new formulation insulin glargine Lantus term occurrence hypoglycemia</brief_summary>
	<brief_title>Comparison New Formulation Insulin Glargine With Lantus® Both Combination With Oral Antihyperglycemic Drug ( ) Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The duration study consist : - Up 2-week screening period ; - 6-month open-label comparative efficacy safety treatment period ; - 6-month open-label comparative safety extension period ; - 4-week post-treatment safety follow-up period</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes mellitus diagnose least 1 year time screen visit treat basal insulin combination oral antihyperglycemic drug ( OADs ) least 6 month screen visit ; Exclusion criterion : Age &lt; 18 year screen visit ; BMI ( body mass index ) ≥ 35 kg/m2 screen visit ; HbA1c &lt; 7.0 % &gt; 10 % ( national glycohemoglobin standardization program [ NGSP ] value ) screen visit ; Diabetes type 2 diabetes mellitus ; Patients selfmonitoring blood glucose le 6 month screen visit ; Patients use premix insulin , insulin detemir 2 time day , GLP 1 receptor agonist last 3 month screen visit ; Patients use mealtime insulin ( rapidacting insulin analogue shortacting insulin ) 10 day last 3 month screen visit ; Use insulin pump last 6 month screen visit ; Initiation new glucoselowering medication and/or weight loss drug last 3 month screen visit ; Severe hypoglycemia result coma/seizures , and/or hospitalization diabetic ketoacidosis last 6 month screen visit ; Unstable proliferative diabetic retinopathy rapidly progressive diabetic retinopathy macular edema likely require treatment ( eg , laser , surgical treatment injectable drug ) study period . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>